Chitosan-Based Nanoparticles for Intracellular Delivery of ISAV Fusion Protein cDNA into Melanoma Cells: A Path to Develop Oncolytic Anticancer Therapies

Figure 3

Effect of treatment with NP-ISAV on tumor growth. (a) Treatment diagram. Mice were injected subcutaneously (s.c.) with living cells in the mouse lumbar region. When the tumor reached 2.0 mm³, mice received, or not (control group), chitosan or NP-ISAV intratumor treatment and were daily monitored until the endpoint criteria. (b) Tumor growth was compared between the nontreated group (control, open circles), the chitosan-treated group (CH, gray circles), and the NP-ISAV-treated group (NP-ISAV, black circles). Representative histograms from tumor-infiltrating T (c) CD8+ (lower panel) and CD4+ (upper panel) cells are shown for untreated mice (control), chitosan treated (CH), or chitosan ISAV nanoparticles (NP-ISAV). (d) A summary of at least 5 independent experiments is shown. Bars correspond to . Individual experiments are graphed; statistical analyses were performed using the Mann–Whitney test ().

(a)

(b)

(c)

(d)